John D Diekman - Net Worth and Insider Trading
John D Diekman Net Worth
The estimated net worth of John D Diekman is at least $115 Million dollars as of 2024-05-25. John D Diekman is the Director of IDEAYA Biosciences Inc and owns about 2,963,066 shares of IDEAYA Biosciences Inc (IDYA) stock worth over $112 Million. John D Diekman is the Director of Affymetrix Inc and owns about 138,296 shares of Affymetrix Inc (AFFX) stock worth over $2 Million. John D Diekman is also the Director of Zai Lab Ltd and owns about 67,615 shares of Zai Lab Ltd (ZLAB) stock worth over $1 Million. Details can be seen in John D Diekman's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John D Diekman has not made any transactions after 2022-02-04 and currently still holds the listed stock(s).
Transaction Summary of John D Diekman
John D Diekman Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John D Diekman owns 15 companies in total, including Aprea Therapeutics Inc (APRE) , IDEAYA Biosciences Inc (IDYA) , and Arvinas Inc (ARVN) among others .
Click here to see the complete history of John D Diekman’s form 4 insider trades.
Insider Ownership Summary of John D Diekman
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
APRE | Aprea Therapeutics Inc | 2019-10-02 | 10 percent owner |
IDYA | IDEAYA Biosciences Inc | 2020-11-11 | 10 percent owner & Former 10% holder |
ARVN | Arvinas Inc | 2018-09-26 | 10 percent owner |
2018-07-17 | 10 percent owner | ||
2018-03-27 | 10 percent owner | ||
2017-11-16 | 10 percent owner | ||
2017-04-24 | other: Fomer 10% owner | ||
2016-05-17 | 10 percent owner | ||
2014-09-23 | 10 percent owner | ||
2015-04-14 | 10 percent owner | ||
2015-02-04 | 10 percent owner | ||
2012-05-11 | director | ||
2022-02-04 | director | ||
2021-12-03 | 10 percent owner | ||
2023-08-18 | 10 percent owner |
John D Diekman Latest Holdings Summary
John D Diekman currently owns a total of 3 stocks. Among these stocks, John D Diekman owns 2,963,066 shares of IDEAYA Biosciences Inc (IDYA) as of May 28, 2019, with a value of $112 Million and a weighting of 97.26%. John D Diekman owns 138,296 shares of Affymetrix Inc (AFFX) as of June 30, 2011, with a value of $2 Million and a weighting of 1.69%. John D Diekman also owns 67,615 shares of Zai Lab Ltd (ZLAB) as of February 4, 2022, with a value of $1 Million and a weighting of 1.05%.
Latest Holdings of John D Diekman
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
IDYA | IDEAYA Biosciences Inc | 2019-05-28 | 2,963,066 | 37.71 | 111,737,219 |
AFFX | Affymetrix Inc | 2011-06-30 | 138,296 | 14.01 | 1,937,527 |
ZLAB | Zai Lab Ltd | 2022-02-04 | 67,615 | 17.92 | 1,211,661 |
Holding Weightings of John D Diekman
John D Diekman Form 4 Trading Tracker
According to the SEC Form 4 filings, John D Diekman has made a total of 1 transactions in IDEAYA Biosciences Inc (IDYA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in IDEAYA Biosciences Inc is the acquisition of 250,000 shares on May 28, 2019, which cost John D Diekman around $3 Million.
According to the SEC Form 4 filings, John D Diekman has made a total of 0 transactions in Affymetrix Inc (AFFX) over the past 5 years. The most-recent trade in Affymetrix Inc is the sale of 10,000 shares on June 30, 2011, which brought John D Diekman around $80,000.
According to the SEC Form 4 filings, John D Diekman has made a total of 4 transactions in Zai Lab Ltd (ZLAB) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Zai Lab Ltd is the sale of 1,000 shares on February 4, 2022, which brought John D Diekman around $50,170.
Insider Trading History of John D Diekman
- 1
John D Diekman Trading Performance
GuruFocus tracks the stock performance after each of John D Diekman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John D Diekman is -46.8%. GuruFocus also compares John D Diekman's trading performance to market benchmark return within the same time period. The performance of stocks bought by John D Diekman within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John D Diekman's insider trading performs compared to the benchmark.
Performance of John D Diekman
John D Diekman Ownership Network
Ownership Network List of John D Diekman
Ownership Network Relation of John D Diekman
John D Diekman Owned Company Details
What does Aprea Therapeutics Inc do?
Who are the key executives at Aprea Therapeutics Inc?
John D Diekman is the 10 percent owner of Aprea Therapeutics Inc. Other key executives at Aprea Therapeutics Inc include President & CEO Oren Gilad , SrVP/CFO/Prin. Fin &Acctg. Off John P. Hamill , and director & President & CEO Christian S Schade .
Aprea Therapeutics Inc (APRE) Insider Trades Summary
Over the past 18 months, John D Diekman made no insider transaction in Aprea Therapeutics Inc (APRE). Other recent insider transactions involving Aprea Therapeutics Inc (APRE) include a net purchase of 16,957 shares made by Bernd R. Seizinger , a net purchase of 6,860 shares made by Henneman John B Iii , and a net purchase of 2,000 shares made by Oren Gilad .
In summary, during the past 3 months, insiders sold 0 shares of Aprea Therapeutics Inc (APRE) in total and bought 16,730 shares, with a net purchase of 16,730 shares. During the past 18 months, 0 shares of Aprea Therapeutics Inc (APRE) were sold and 26,827 shares were bought by its insiders, resulting in a net purchase of 26,827 shares.
Aprea Therapeutics Inc (APRE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aprea Therapeutics Inc Insider Transactions
John D Diekman Mailing Address
Above is the net worth, insider trading, and ownership report for John D Diekman. You might contact John D Diekman via mailing address: C/o 5 Am Ventures, 501 2nd Street, Suite 350, San Francisco Ca 94107.